This is a working overview of Heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-24. Anything still debated is marked as such rather than presented as settled.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
===== Break ===== "The Bolivarian Republic of Venezuela has decided, in the full exercise of its sovereignty, to break diplomatic relations with the Republic of Paraguay and to proceed with the immediate withdrawal of its diplomatic personnel accredited in that country".- Statement by the Venezuelan executive (c. January 2025). Venezuela broke diplomatic relations with Paraguay on 6 January 2025 due to Santiago Peña's recognition of Edmundo González Urrutia as the winner of the election in Venezuela. Caracas considered this interference in its internal affairs and withdrew its diplomatic personnel from Asunción. In response, the Paraguayan government reaffirmed its support for González Urrutia and demanded the departure of the Venezuelan ambassador and his team within 48 hours.
ALS Alzheimer's disease, Bipolar disorder, schizophrenia, aging and senescence, anxiety disorders Cancer Cardiovascular disease Diabetes Huntington's disease Long Covid ME/CFS Parkinson's disease Sarcopenia The body, and each mutation, is modulated by other genome variants; the mutation that in one individual may cause liver disease might in another person cause a brain disorder. The severity of the specific defect may also be great or small. Some defects include exercise intolerance. Defects often affect the operation of the mitochondria and multiple tissues more severely, leading to multi-system diseases. It has also been reported that drug tolerant cancer cells have an increased number and size of mitochondria, which suggested an increase in mitochondrial biogenesis. A recent study in Nature Nanotechnology has reported that cancer cells can hijack the mitochondria from immune cells via physical tunneling nanotubes. As a rule, mitochondrial diseases are worse when the defective mitochondria are present in the muscles, cerebrum, or nerves, because these cells use more energy than most other cells in the body. Although mitochondrial diseases vary greatly in presentation from person to person, several major clinical categories of these conditions have been defined, based on the most common phenotypic features, symptoms, and signs associated with the particular mutations that tend to cause them. An outstanding question and area of research is whether ATP depletion or reactive oxygen species are in fact responsible for the observed phenotypic consequences.
For services to the Meat Industry. Kenneth Adams-Morgan. For Political Service. Ronald Morgan, Deputy Governor and Head of Custody, Her Majesty's Prison Noranside. Richard William Morley, lately Catering Manager, Ring & Brymer (City). For services to the Catering Industry. Kathnne Amanda Morris, Clerk to the Corporation, East Birmingham College. For services to Education. Donald Fergusson Morrison, District Registrar, Strachur, Argyll. For services to the community. Mane Morrow. For services to disabled people. Walter Kenneth John Mummery, lately Principal Prison Officer, Her Majesty's Prison and Young Offenders' Institution Moorland. Joan F. Munro, Speech and Language Therapy Manager, Highland Communities NHS Trust. For services to Health Care. Robert Nathaniel Murray. For services to the community in Derby. The Reverend Canon James Robert Musgrave. For services to the community. Samuel Newgarth. For services to Music and for charitable services in Dorset. Jeanne Marjorie Nicholls, President, Cornwall and Isles of Scilly Leagues of Hospital and Community Friends. For services to Health Care. David Edgar Thomas Nichols, Senior Scientific Officer, the Defence Evaluation and Research Agency, Ministry of Defence. Mary Nimmons. For services to Health Care. The Reverend Canon Richard Henry Norburn. For services to the community in Bury St Edmunds, Suffolk. Doreen Norgrove. For services to the community in Farnham, Surrey. Sheila Norman, Chairman, Royal Life Saving Society, Suffolk Branch, and Commonwealth Development Liaison Officer, Royal Life Saving Society UK.
Sources: en.wikipedia.org
The confidential documents, codenamed Vault 7 and dated from 2013 to 2016, include details on CIA's software capabilities, such as the ability to compromise cars, smart TVs, web browsers (including Google Chrome, Microsoft Edge, Mozilla Firefox, and Opera Software ASA), and the operating systems of most smartphones (including Apple's iOS and Google's Android), as well as other operating systems such as Microsoft Windows, macOS, and Linux. In June 2019, The New York Times reported that American hackers from the United States Cyber Command planted malware potentially capable of disrupting the Russian electrical grid. The United States topped the world in terms of cyberwarfare intent and capability, according to Harvard University's Belfer Center Cyber 2022 Power Index, above China, Russia, the United Kingdom and Australia. In June 2023, the National Security Agency and Apple were accused by the Russian Federal Security Service (FSB) of compromising thousands of iPhones, including those of diplomats from China, Israel, NATO members, and Syria. Kaspersky Lab said many of its senior staff and managers were also hit by the ongoing attack, which it first suspected in early 2023. The oldest traces of infiltration date back to 2019. Kaspersky Lab said it had not shared the findings with Russian authorities until the FSB announcement.
Sample warming can be controlled by bead beating for short time intervals with cooling on ice between each interval, by processing vials in pre-chilled aluminum vial holders or by circulating gaseous coolant through the machine during bead beating. A different bead beater configuration, suitable for larger sample volumes, uses a rotating fluorocarbon rotor inside a 15, 50 or 200 ml chamber to agitate the beads. In this configuration, the chamber can be surrounded by a static cooling jacket. Using this same rotor/chamber configuration, large commercial machines are available to process many liters of cell suspension. Currently, these machines are limited to processing unicellular organisms such as yeast, algae and bacteria.
=== Appearance and form === DMT is commonly handled and stored as a hemifumarate, as other DMT acid salts are extremely hygroscopic and will not readily crystallize. Its freebase form, although less stable than DMT hemifumarate, is favored by recreational users choosing to vaporize the chemical as it has a lower boiling point. DMT is a lipophilic compound, with an experimental log P of 2.57.
Sources: en.wikipedia.org
== History == Salvia divinorum has been used as an entheogen by the Mazatec people of Mexico for hundreds of years. The American anthropologist Jean Bassett Johnson made expeditions to Mexico in the mid-to-late 1930s, observed the entheogenic use of Salvia divinorum by the Mazatecs there, and was the first to describe the existence of the plant in 1939. Subsequently, other researchers, including Blas Pablo Reko and Robert J. Weitlaner, also described the plant and its use in the 1940s and 1950s. Arturo Gómez-Pompa classified the plant as belonging to the genus Salvia in 1957, but was unable to completely identify it at the time due to absence of flowering material. Finally, Robert Gordon Wasson and Albert Hofmann collected flowering specimens of the plant in the early 1960s and sent them to Carl Epling, the leading expert on the Salvia genus of the time, who defined the plant as a new species named Salvia divinorum in 1962. Salvinorin A was isolated from Salvia divinorum and identified by Alfredo Ortega and colleagues in 1982. They used a combination of spectroscopy and X-ray crystallography to determine the chemical structure of the compound, which was shown to have a bicyclic diterpene structure. Around the same time, Leander Julián Valdés III independently isolated the molecule as part of his doctoral research, published in 1983. Valdés named the chemical divinorin, and also isolated an analogue that he named divinorin B. The naming was subsequently changed to salvinorin A and salvinorin B after the work was published in 1984. Valdés later isolated salvinorin C as well.
Cyclophosphamide (Cytoxan, Procytox), Doxorubicin (Adriamycin) and Vincristine (Oncovin) Paclitaxel (Taxol) Irinotecan (Camptosar) Guidelines recommended as of 2018 that patients who relapse > 6 months from initial therapy should be retreated with the original chemotherapy regimen. For patients who relapse in < 6 months, single-agent chemotherapy either topotecan second-line therapy, or paclitaxel can be used.
=== Army leadership resignations === In April 2026, Hegseth fired Army Chief of Staff Gen. Randy George which has left the longest break without a service chief in Army history and making him one of eight high ranking members of the military fired or forced out by the secretary of defense. On August 31, 2026 Secretary of the Army Dan Driscoll gave Hegseth his resignation after a face to face meeting Driscoll had with President Trump where he stated his concerns over the number of army generals fired under Hegseth.
=== Brazil === Between 2005 and 2021, Brazil had 1,576 suspected cases of CJD, of which 547 were confirmed. In August 2026, Brazilian aviation expert Lito Sousa was diagnosed with CJD. He died two months later, on October 1.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.